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Position Statement 
 
Pre-existing malignancies in renal transplant candidates –  time to reconsider 
waiting times ! 
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Introduction 
Transplantation has evolved as the gold standard for renal replacement 
therapy based on better life quality and important survival benefits compared 
to hemo- and peritoneal dialysis. [1, 2] Consequently a major treatment goal 
for patients with end-stage renal disease (ESRD) is offering renal 
transplantation for as many patients as possible. 
 
In preparation for a kidney transplant, potential candidates must undergo pre-
transplant screening programmes that include a precise immunological work-
up and focus on pre-existing medical conditions such as cardiovascular 
diseases, infections and the presence of any active and/or history of 
malignancy [3]  Serious medical conditions or a high number of comorbidities, 
increase the risk for dying during or shortly after transplantation and therefore 
can prohibit or postpone the patient´s acceptance onto the waiting list.  
 
New epidemiological data, recent developments in oncology and changes in 
immunosuppressive therapy may allow a re-evaluation of current practice for 
listing of patients with a variety of tumour entities. Albeit important, it is 
beyond the scope of this position statement to go into a detailed discussion of 
all individual malignancies, as different genomic properties, tumor stages and 
treatment opportunities/modalities may nowadays significantly influence the 
decision processes. We focused on solid tumors and try to provide a general 
overview on evolving issues. 
 
In recipients with a pre-transplant malignancy, cancer mortality seems about 
doubled to tripled compared to recipients without a history of cancer.  
Whether overall mortality is also increased is debatable, with reports from 
Scandinavia finding no or only slightly increased relative risk of all-cause death 
(6-20%) [4, 5], whereas a review of UK and US cohorts reported a 53% increase 
in all-cause death. A similar long term all-cause mortality risk (HR 1.88) can be 
found for patients with pretransplant cardiac events, [6] Waitlisting of  patients 
with a prior cardiovascular event has become less debated and is common 
practice. Active listing of patients with pre-existing malignancies however, is 
often postponed, because of a fear of cancer recurrence and/or the effects of 
post-transplant immunosuppression which is often incriminated of  reactivating 
and aggravating the malignant disease.  
 
Of note, the absolute long-term risk of mortality due to cancer recurrence 
seems to be relatively modest at about 10-15% [4, 5], and tumour recurrence 
rate was reported to be 2.4 per 100 person-years [7] These figures need to be 
interpreted in the context of a dialysis-related mortality of 5% per year.  
(https://www.eurotransplant.org/cms/mediaobject.php?file=Eurotransplant+J
V+PDF.pdf ) 
 
 
The rationale for malignancy screening in transplant candidates 
 
Malignancies are a leading cause of morbidity and mortality after 
transplantation [8-13] and reviewed in [14]. Transplant candidates are at 
increased risk for a variety of cancers compared to the general population [15-
18] and prognosis for several common cancers may be worse in transplant 
patients than in the general population [19, 20]  
Transplant candidates need to undergo a thorough evaluation process before 
the operation. The presence of an active malignancy is a contraindication for 
renal transplantation. Patients must be in tumour remission for some time (the 
time span may vary depending on the type of malignancy) before being 
considered for transplantation. Previous recommendations for transplant 
candidates were typically compiled without involvement of oncologists or 
screening specialists and were not well validated. According to guidelines, 
screening in ESRD patients is usually performed following the same protocols 
suggested for the general population. [21-23] 
 
Malignancy risks in dialysis and transplant patients 
Malignancy risk is usually expressed as the standardized incidence ratio (SIR) 
which compares the respective incidence of a malignancy with the rate found 
in the general population. Transplant recipients are known to have increased 
SIRs for many types of malignancies. [17, 24, 25] It has to be appreciated, 
however, that dialysis patients also have increased tumour rates, [26-28] that 
for many malignancies do not differ significantly from rates in transplant 
recipients [25] (Table 1). Some, but not all types of cancer occur more often 
after transplantation. Cancers with particularly higher frequencies after 
transplantation include Kaposi sarcomas, lymphomas, lip, vulvovaginal , penile- 
and anal carcinomas, and non-melanoma skin cancers [17, 24, 25, 29]  
 
  
Table 1 
 
Relative risk of cancer among first-time recipients of deceased or living donor 
kidney transplantation (compared with cancer while on the waiting list in 
1995–2001 (n = 35 765) ; adapted from [25] 
 
Tumors with RR (relative risk) >1  
 
Type of cancer RR (95% CI) p-value 
    
Kaposi sarcoma 9.03 (2.58-31.6) 0.0005 
Non-Hodgkin’s lymphoma 3.29 (2.40-4.51) <0.0001 
Esophagus 2.76 (1.03-7.37) 0.0428 
Hodgkin’s lymphoma 2.60 (1.01-6.68) 0.0471 
Skin 2.55 (2.26-2.88) <0.0001 
Melanoma 2.19 (1.31-3.65) 0.0028 
Mouth 2.19 (1.33-3.61) 0.0022 
Vulvovaginal 2.19 (0.67-7.12) 0.1936 
Any hematopoietic 2.04 (1.64-2.53) <0.0001 
Breast in men 1.88 (0.32-10.9) 0.4834 
Leukemia 1.59 (1.03-2.45) 0.0355 
Kidney 1.39 (1.10-1.76) 0.0058 
Cervix 1.28 (0.48-3.36) 0.6230 
Central nervous system 1.27 (0.78-2.06) 0.3304 
Any non-skin 1.17 (1.07-1.28) 0.0004 
Any genitourinary in women 1.16 (0.86-1.56) 0.3425 
Bladder 1.12 (0.73-1.70) 0.6098 
Lung 1.05 (0.79-1.40) 0.7241 
Any genitourinary in men 1.02 (0.86-1.21) 0.8592 
 
Tumors with RR (relative risk) < 1  
Breast in women, Uterus , Ovary, Prostate, Testis, Endocrinologic  
Stomach, Hepatobiliary, Pancreas, Small intestine, Colon  
Myeloma, Bone, Larynx, 
 
CI = confidence interval 
  
 
Comparing malignancy risks post-transplantation with those while remaining 
on dialysis (i.e. relative risk between the ESRD modalities, rather than absolute 
risk compared to the general population without renal disease) is more 
relevant for an ESRD patient (Table 1). From a transplant patient´s or transplant 
candidate´s perspective SIRs, which express the risk compared to the general 
population are of limited value as dialysis is the transplant patient´s sole 
alternative survival option. Therefore, the relevant risk of cancer development 
post-transplantation should be the risk compared to cancers developing whilst 
on dialysis. A high SIR after transplantation should not be the sole reason for 
withholding a kidney transplant, especially if the SIR for a respective tumour is 
equally high in a dialysis patient. This may be particularily true in the case of 
living donation where both the donor and recipient can be adaequately 
informed and would have a good understanding of the risks involved.  
An argument that is often used against transplanting patients with a history of 
cancer is that kidneys from deceased donors are scarce and should perhaps be 
allocated to lower risk individuals. Whether this argument, that could be 
equally used for other high risk situation such as diabetes or heart disease is 
ethically justifiable, remains open for discussion. Transplants in patients with 
pre-existing malignancies may be regarded more favourably in countries with a 
high deceased donor transplant acitivity and shorter waiting times than in 
regions where the waiting times are exceptionally long due to a low number of 
donor organs.  
 
It can be expected that the overall health status of a patient with ESRD will 
considerably improve after receiving a functioning kidney transplant. 
Nevertheless, a potential increase in malignancy-risk and its associated impact 
on quality and length of life post transplantation has to be balanced against the 
expected overall health benefit. (Figure 1 and Table 1) [26-28]  
In a recent review Acuna reported a recurrence rate of 2.4 per 100 person-
years in kidney transplant recipients and concluded that the risk of cancer 
recurrence in recipients with pretransplant malignancies  is considerably lower 
than in historic reports that formed the basis for current waiting time 
recommendations [7]  
 
The fear of a potential cancer recurrence can lead to a delay of transplantation. 
The competing malignancy-independent mortality risk inherent to remaining 
on long-term dialysis, i.e. 5% per year [30], however,  needs to be taken into 
account. Patients should be informed about these different competing risks 
and be given the opportunity to consent for earlier or later wait-listing and 
transplantation.  
 
  
 
Figure 1  
 
Risks for Malignancy and Mortality are elevated in dialysis patients as well as in transplant 
recipients when compared to the general population. Renal transplantation may increase 
the risk for malignancies, but the potential survival benefit in transplant recipients compared 
to patients remaining on dialysis should be taken into account when waiting times are 
defined in transplant candidates.  
 
Dialysis time as a determinant for reduced survival 
 
Dialysis duration constitutes a potentially modifiable factor for the survival of 
ESRD patients [31]. Patients undergoing pre-emptive transplantation have a -
survival benefit compared to those who already initiated haemodialysis [32, 
33]. Similarly, early transplantation as soon as possible after the start of dialysis 
leads to improved long term survival as compared to transplantation after a 
prolonged period of dialysis [34-37]. Remaining on dialysis has consistently 
been associated with a 5% yearly mortality  
(https://www.eurotransplant.org/cms/mediaobject.php?file=Eurotransplant+J
V+PDF.pdf ) 
These observations make it clear that any uncritical decision to delay a 
transplant should be avoided, as it may negatively influence the patient´s long 
term survival. Even if a potentially higher risk of cancer or of a recurrence of a 
pre-existing malignancy may have a negative impact on patient survival, a 
restrictive transplantation policy leading to an inappropriately long cancer-free 
waiting time may ultimately be disadvantageous for the overall survival of the 
patient.  
 
Dialysis time as a determinant for increased risk of malignancy 
 
Incidence ratios (SIR) for malignancies are increased in dialysis patients. [30, 38, 
39] SIR´s in patients dialyzed in the 1980s in USA, Europe, Australia, or New 
Zealand were 1.18, with higher rates for cancers of the kidney (SIR, 3.60), 
bladder (SIR, 1.50), thyroid and other endocrine organs (SIR, 2.28). [26]  
Between 1996 and 2009 the SIR was 1.42 in an unselected dialysis cohort 
included in the US Medicare’s ESRD programme with the highest risk for 
cancers of the kidney/renal pelvis (SIR, 4.03) and bladder (SIR, 1.57). [30] 
With an increase of dialysis duration, the 5-year cumulative incidence of any 
cancer rises to almost 10% (Figure 2a). [30] In an Italian single centre study in 
wait-listed dialysis patients (the most appropriate control group for 
transplanted patients), the cancer risk also rose over time and cumulated to 
almost 5% after 5 years. The overall risk (SIR, 1.4) was within the published 
range for dialysis patients and less than in transplant recipients (SIR, 2.1). [40] 
The increase of cancers after transplantations was in accordance with the 
observations by Vajdic et al., mainly attributable to cancers associated with 
viral infections.[17, 40]  
These data show that remaining on dialysis (instead of being transplanted) 
does not alleviate the risk for developing cancer, but that the cancer risk is 
likely to cumulate with increasing time on dialysis. The increasing age of dialysis 
patients and transplant candidates may further aggravate the problem. 
The 5% cumulative incidence after 5 years in the wait-listed Italian dialysis 
patients corresponds well with the cumulative incidence of all cancers 
(excluding non-melanoma skin cancer and independent of mTOR Inhibitor use) 
in first deceased-donor kidney transplants (1999–2013) reported from the 
Collaborative Transplant Study [41] (Figure 2b), demonstrating that ESRD 
patients are at a significant malignancy risk, independent of the treatment 
modality.  
Figure 2 a 
 
Figure 2aCancer Incidence increases with time on dialysis 
In hemodialysis patients the 5-year cumulative incidence of any cancer is 9.48%. 
(Results accounting for death as a competing event) (with permission from 
[30]) 
 
Figure 2 b  
 
 
Figure 2 b  
Cancer Incidence increases with time after transplant  
Cumulative incidence of all cancers (excluding non-melanoma skin cancer) in 
propensity score matched first deceased-donor kidney transplants (1999–2013) 
reported from the Collaborative Transplant Study treated with or without 
mTOR Inhibitors (with permission from [41]) 
 
Post-transplant immunosuppression as a risk factor for malignancy 
 
The increased risk for certain malignancies after transplantation is probably 
due to an immunosuppression-induced loss of normal immune surveillance 
mechanisms in combination with an increased prevalence of viral infections  
involved in the pathogenesis of cancer. [25, 42]  
Well known examples of virally induced malignancies are Kaposi sarcoma 
(Human Herpesvirus 6), non-Hodgkin-lymphoma (EBV), and cervical, 
anogenital, oral cavity, and oropharyngeal cancers (Human Papillomavirus). 
The link between immunosurveillance and virally-induced cancers is further 
underlined by the possibility of tumour reversal through reduction of 
immunosuppression in cancers with a confirmed infectious cause, such as EBV-
related post-transplant lymphoproliferative disease. In contrast, reduction of 
immunosuppression does not significantly alter the course of other cancers, 
especially those related to end stage kidney disease. [43] 
The role of immunosupressants for facilitating tumour development was 
recently reviewed by Acuna and de Fijter [14, 44] 
mTOR Inhibitors seem to be advantageous for Kaposi sarcoma, mantle cell 
lymphoma and non-melanoma skin cancers, whereas for most other cancers 
equal benefits could not be shown. [44]. With regard to other drug classes the 
cumulative dose of the individual drug (e.g. T-cell depleting agents and non-
Hodgkin lymphomas) and/or the cumulative total  immunosuppression plays a 
relevant role. Il-2 receptor antibodies used as induction therapy do not confer 
an additional malignancy risk. [14] Whether new protocols (e.g. steroid sparing 
regimes or the use of belatacept) will have a longterm beneficial effect on 
tumor recurrence can hopefully be answered in the future. 
 
In contrast, other types of cancer do not differ significantly between dialysis 
and transplant patients. [45] The risk for non-virally related solid cancers 
observed in dialysis patients, increased by 19% after transplantation (age 
standardized rate ratio (ASRR) = 1.19) in Italian patients as compared to a ASRR 
of 1.85 for all de novo cancers. [40] Mechanisms, such as sun light, may exert a 
negative impact on non-virally triggered tumorgenesis and may explain a 
higher frequency of skin cancers in transplant recipients.  [46] 
In addition direct, non immune mediated  effects of immunosuppressives (e.g 
cyclosporine, azathioprine) may contribute to skin cancer development. [47] 
In a large transplant cohort (1970-2008), recipients with a cancer history before 
transplantation had a 30% increased mortality risk after transplantation. This 
risk was moderately elevated for recipients of a kidney (HR 1.2 95%: 1.0-1.4) 
but clearly higher in recipients of other organs (HR 1.8), indicating that the type 
of transplanted organ and the corresponding intensity of immunosuppression 
also influences the cancer risk. [4] Additional factors playing a contributory role 
for malignancies after kidney transplantation are summarized in Table 2. 
 
Table 2  
Factors contributing to increased rates of malignancies after kidney 
transplantation 
 
 Older Age 
 Male Gender 
 Longer time on dialysis 
 Smoking 
 Sun light exposure 
 Prior malignancy 
 Increased total immunosuppression 
 Azathioprine 
 T-cell depleting antibodies 
 
Reasons to reconsider the traditional “2-or-5-year-waiting-time-rule” for 
patients with pre-existing malignancies 
 
In his seminal paper in 1993, Penn reported that the time between pre-
transplant cancer occurrence and transplantation impacts on the risk of cancer 
recurrence after the operation [48]. Penn suggested that disease free intervals 
should be observed before a transplant is undertaken. These suggestions were 
based on a very limited number of cancer cases (collected in Penn´s voluntary 
and by that nature incomplete Cincinnati registry).  Nevertheless, being the 
best evidence at the time, Penn´s report was the major source for 
recommendations published in subsequent guidelines. (Reviewed in [49])  
Most guidelines advised a cancer-free waiting time between 2 and 5 years for 
most cancers, depending on the cancer type.  These recommendations were 
published more than 5 years ago and were summarized by Batabayal et al. in 
2012. [49-52] More recently, the ERBP working group suggested (in an 
Ungraded Statement)  that patients with current or previous cancer should be 
discussed with an oncologist and that waiting time should be considered on a 
case-by-case basis taking into account the following issues: “ (a) the potential 
for progression or recurrence of the cancer according to its type, staging and 
grade; (b) the age of the patient; (c) the existence of comorbidities.” 
  
Penn´s initial recommendations are cautious and based on concerns that 
patients may be deliberately exposed to cancer recurrence and an avoidable 
mortality risk, if they are transplanted too early. It should be appreciated, 
however, that a prolonged waiting time on dialysis may reduce the likelihood of 
cancer recurrence but at the same time may not change the risk for de novo 
malignancies and even increase the risk of death from other causes. [4, 53] 
Unfortunately a decision model to determine at which time point the balance 
tips in favour of a transplant, is yet to be developed. 
 
 
Studies on the risk of recurrence and on mortality in ESRD patients with a 
history of malignancy 
 
Cancer recurrence rates in transplant recipients vary between 1 and 25% 
depending on the type of cancer. [51, 54-56] Existing studies focused on 
recurrences in transplant patients with pre-existing malignancies and 
compared the rates to initial tumour-naïve recipients.  
It is less clear, if recurrence rates differ significantly in patients who remain on 
dialysis or who receive a kidney transplant. This information, however, would 
be most relevant for a dialysis patient who had suffered from a malignancy and 
who wants to get a qualified estimate of the change in his/her recurrence risk if 
transplanted. Respective data are still to be collected. 
 
A recent UK Study (median follow-up 4.4 yrs of 19103 kidney transplants 
performed between 2001 and 2012), in which only 0.4% of the study 
population (n= 74) had a history of malignancy at the time of transplantation, 
found a higher risk (17.6%) in cancer-specific mortality in transplant recipients 
with previous cancer compared to recipients without previous cancer (1.9%). 
The study did not distinguish between recurrent or de novo malignancies and 
did not compare the results to risks of patients who remained on dialysis. [57] 
In a large population based cohort in Sweden, kidney recipients with a history 
(versus no history) of malignancy had a slightly elevated risk (HR 1,2) of death 
after the transplant, which was primarily driven by cancer recurrence.  
[4] Acuna et al. demonstrated in their meta-analysis in transplant patients with 
pre-existing malignancies in remission, that all-cause mortality risk was similar 
for kidney (HR 1.53) and non-kidney (HR 1.61) recipients,  when compared to 
patients without pre-transplant malignancy. In general, pre-transplant 
malignancy (vs. none) was associated with increased risk of all cause-mortality, 
cancer-specific mortality and development of de novo malignancies after solid 
organ transplantation (including kidneys). [53]  
 
Using competing risk analysis in a population based study in patients from 
Ontario, Canada, Acuna et al., demonstrated that patients with pretransplant 
malignancy had an increased risk of both cancer-specific (HR, 1.85) and 
noncancer death (HR, 1.29), compared to recipients without pretransplant 
malignancies. In addition, patients who waited more than 5 years from 
malignancy diagnosis to transplantation had an increased risk of noncancer 
death. Only patients  with high-risk malignancies were at increased risk for 
cancer-specific mortality (HR, 3.16). Patients with low risk malignancies (as 
defined by the authors: thyroid, prostate, bladder, kidney, oropharynx, or 
testis) did not have an adverse outcome if transplanted within 5 years of cancer 
diagnosis, but had an increased risk of death (HR, 1.76) similar to high risk 
patients if they were transplanted more than 5 years after cancer diagnosis. 
[58, 59] 
 
 
A recent Norwegian study in a cohort of 5867 kidney transplant recipients 
reported results of a generally shortened 1-year recurrence-free waiting time 
after cancer occurrence. In this cohort, 6.4% of the transplant population had a 
pre-transplant cancer. Despite an increased cancer mortality particularly during 
the first 5 years after transplantation, ”recipients with a pretransplant cancer 
had a similar overall patient and graft survival as recipients without such 
cancer. A short waiting period was not associated with recurrent cancer 
mortality or all-cause  mortality.” [60]  
In an analysis of the Australian and New Zealand Dialysis and Transplant 
Registry, the survival in patients with a cancer recurrence was not different 
from patients who developed a first cancer after the transplant or a second 
primary cancer. Altogether recurrent cancers were infrequent events in this 
patient series, which was certainly carefully and conservatively selected with 
respect to the waiting time. Only three percent of transplant recipients 
between 1965 and 2012; n=651 of 21,415) had a previous cancer history and 
only 23 (0.8%) of them experienced a cancer recurrence. [20] In Norway the 
proportion of transplant recipients with a history of cancer was equally low 
(2,6%) in the early era (1963-1882). The significant increase to 8,9% in the 
period from year 2000 to 2010 indicates that pre-existing malignancy is now 
increasingly frequent and needs to be adequately addressed as an important 
clinical challenge in the future. [60] 
 
 
Lack of studies reporting detailed information on cancers  
In contrast to immunological issues (type of immunosuppression, rejection 
rates etc.) information on malignancies and related outcomes were hardly ever 
central to structured data collections in the field of transplantation. Thus the 
malignancy data in renal transplantation is still scarce and incomplete. The 
most recent comprehensive review on outcomes of urological cancers in 
patients, who either remained on dialysis or received a transplant exemplifies 
this fact. Despite all efforts, the study reports on only 439 transplant patients 
with renal cancers, 161 cases of prostate cancer and 137 urothelial cancer 
cases. [61] Equally low or even lower numbers of cases are reported for other 
tumours in recent reviews [17, 62-65] 
 
Previous reports on cancers in transplantation were usually limited to the type 
of tumour and the time between its treatment and kidney transplantation. [52] 
Typically, more granular or elaborate clinical information was not available. 
These studies no longer reflect the epidemiology of patients seen during the 
transplant evaluation process today. Over the last decade, more detailed 
staging algorithms including histological and molecular sub-classification have 
been developed. With the availability of genetic testing, cancers can often be 
divided into many different biological subtypes. These refined classifications 
have led to a more precise selection of anti-tumour therapies and facilitated 
better therapy outcomes or even cure from malignancies. 
 
Renal cell carcinoma is a good example in this respect. The histological subtype 
has been identified as one indicator impacting the recurrence risk in addition to 
stage and grade (reviewed in [61]). Leibovich et al. showed in a non-transplant 
population that clear cell carcinomas of the kidney have a significantly worse 
outcome than papillary or chromophobe subtypes with regard to recurrence. 
Taking histology into account and combining it with grade and stage, a 
respective scoring system identifies low, intermediate and high risk patients. 
[66].  This classification could be of value to individualize and potentially reduce 
waiting times in patients on the waiting list for a kidney transplant. Findings 
from a recent French study suggest that histological type clear cell RCC (13% vs 
0% in papillary RCC), Tumor stage pT2 and Fuhrman grade IV are factors 
associated with a higher risk of cancer recurrence. However, there is no 
correlation between post-transplant recurrence and the interval before 
transplantation [67]  
The issue of kidney cancer in polycystic kidney disease (PKD) patients is  a 
matter of debate. While cancers in PKD are more prevalent when comared to 
the general population, they seem to be less common after transplantation in 
PKD patients than in unaffected individuals. Patients with acquired cystic 
kidney disease, however seem to carry a higher risk after transplantation [14]   
 
A subset of renal cell carcinomas may be relatively benign, as suggested by a 
series of asymptomatic patients that underwent native nephrectomy at the 
time of transplantation. In this cohort, RCCs were found in 4,2 % of cases 
without having an effect on graft function or patient survival post-
transplant.[68] It is thus tempting to speculate that patients with undetected 
small RCC may have been transplanted in the past without significant problems 
thereafter.  
In patients with a low risk for the development of metastasis or recurrence, a 
short waiting time for a transplant would  therefore seem to be justifiable. A 
longer waiting time may not be advantageous, as the risk of renal cancers also 
increases with a prolonged time on dialysis. [69]  In addition, the overall 
mortality risk on dialysis may even exceed the tumour recurrence risk. On the 
contrary, symptomatic or large renal cell carcinomas, with recurrence rates of 
greater than 25% may warrant a longer interval between successful treatment 
and transplantation.  [48, 70, 71] In children with Wilms tumor the 2-year 
waiting time period has recently been challenged for patients with low risk 
disease. [72] 
 
Likewise, in prostate cancer a beneficial histological grade may allow a 
shortened waiting period [61]. For some tumours, a lack of recurrence after 
one or two years virtually suggests a complete cure of the tumour. Following a 
cautious approach it could make sense to wait for this respective period. For 
other cancers (like breast cancer) the risk of recurrence does not clearly 
subside over time, thus one could argue that there is no rational cut-off value 
for waiting time in these cases.  
For certain PTLD cases it was recently suggested that after treatment re-
transplantation is feasible, but that a waiting time of at least 1 year may be 
reasonable[73] 
 
In the future the assessment of an individual's genetic profile may also be 
helpful for deciding on the appropriate waiting time. Two patients with ESRD 
and breast cancer were identified as low risk individuals by genomic profiling 
assays, leading to a decision to transplant way before the suggested waiting 
period was over. In one, transplantation was performed 1 year, in the other 
subject 1,5 years after breast cancer diagnosis. The patients remain tumour 
free six and five years after the operation, respectively. [74] 
With rapid developments in the field of oncology case-by-case discussions with 
an oncologist in patients with current or previous cancer, as already suggested 
by the ERBP Guidelines will become even more relevant for the benefit of the 
patients in the future. [75] 
 
 
 Conclusions 
 
With the aging population of transplant-candidates and transplanted patients, 
malignancies pre and post kidney transplantation are becoming increasingly 
important. As a transplant community we should start to focus on the 
emerging problem of malignancies and collect additional and more detailed 
information in a prospective manner. This will allow making well-informed 
decisions for our patients in the future. 
Previously suggested waiting times, which were mainly based on a very limited 
numbers of cases seem to be disputable in the light of novel tumour 
stratifications and the advent of various new anti-tumour therapies. It is 
important to realize that withholding transplantation does not necessarily 
preclude cancer occurrence in renal patients and that the likelihood of tumour 
recurrence also rises with increasing time on dialysis. On top of the tumour risk, 
remaining on dialysis carries an additional mortality risk when compared to 
being successfully transplanted. Balancing the risk of malignancy with other 
dialysis-associated risks is warranted. 
 
Transplant decisions in pre-transplant patients with malignancies should be 
made together with oncologists on an individual basis. This additional effort, 
even though increasing the workload for the specialists involved, may result in 
a significant benefit for the patient if waiting time can be shortened by a 
refined and individualized, yet critical decision. The risk of cancer recurrence 
seems to be mainly influenced by tumour type rather than the length of 
waiting time. A detailed histological subclassification and the use of genetic 
markers will be helpful for future identification of subgroups of patients at 
heightened risk of malignancy or recurrence (see Websites such as 
lifemath.net/cancer  of the Laboratory for Quantitative Medicine of the 
Harvard Medical School and Massachusetts General Hospital for useful 
information) and to guide waiting time taking into account tumor 
heterogeneity.  
 
A collective effort in prospectively collecting detailed malignancy data 
(compared to the crude information available to Penn 25 years ago) is 
necessary (Table3). This process should involve transplant physicians and 
oncologists specialized in respective tumour entities and should ultimately 
result in better defined risk benefit ratios and new treatment strategies and 
recommendations for transplant patients with malignant disease. These would 
allow a full and frank discussion with prospective transplant recipients, 
enabling them to make the optimal treatment choice relevant to their 
condition and their threshold of risk-taking, in particular in living, but also in 
deceased donor transplantation  
 
It is the aim of this statement to acknowledge new thoughts on pre-exsiting 
malignancy and transplantation. Earlier recommendations of waiting times for 
a transplant were based on a paucity of data and the fields of oncology, 
transplantation and genomic profiling have significantly improved in recent 
years. We hope to stimulate  discussions for individual patient evaluations 
whenever applicable  that may lead to shorter waiting times for some patients 
using new oncological diagnostic measures and experience. 
 
Table 3 Areas where more research is urgently required 
 
 Comprehensive prospective collection of malignancy data in kidney 
transplant data bases 
 Comparative analysis of cancer recurrence in waitlisted and transplanted 
ESRD patients 
 Prospective collection of granular data on tumour biology including 
genomic profiling in transplant candidates and patients 
 Evaluation of tumour frequencies and  characteristics under different 
immunosuppressive protocols (CNI free, steroid free etc.) 
 
Key points 
 
 Malignancies represent an emerging problem in the ageing population of 
transplant candidates. 
 
 Remaining on dialysis is associated with an increasing cancer and 
mortality risk. 
 
 Current recommendations for waiting times need to be reconsidered and 
may be shortened for a variety of malignancies. 
 
 Waiting times should be defined together with an oncologist on an 
individual basis. 
 
 Additional and more detailed information on malignancies should be 
collected in a prospective manner.  
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